I was pleasantly surprised by how much l learned at the McDermott Will & Emery Life Sciences Deal-making symposium last week. I don’t say that by inferring I know a lot, in quite the opposite, but what I mean is that a lot of conferences and events are the same content but with different names … Continue reading A Recap of the McDermott Will & Emery Life Sciences Deal-making Symposium
Are we in a biotech IPO bubble? Two things have clearly happened over the past few years within this sector. First, pre-money valuation has gone way up, roughly a 130% increase from the 2012-14 period which was a comparably active period to today. Secondly, a larger percentage of companies are Phase II or earlier. That … Continue reading Are We In A Biotech IPO Bubble?
One of the most common questions I get asked comes from Pre-Clinical Life Science companies is why do I need insurance? I agree that pre-clinical life science companies have about as little risk as a company can have. Why they need insurance really comes down to contracts, investors and statutory regulations. If the company enters … Continue reading Common Question Friday – Why Do Pre-Clinical Companies Need Insurance?